Indonesia-based healthtech startup Bumame has raised an undisclosed sum in a pre-Series A funding round led by Alpha JWC Ventures.
500 Global and Kopital Ventures joined the round.
The new funding will enable Bumame to accelerate its digital transformation and expand its healthcare offerings, focusing on early detection, fast and accurate diagnostic results, and tailored health insights to empower individuals to make informed decisions about their health.
Established in 2020, Bumame initially provided accessible COVID-19 testing services to millions of Indonesians. Building on this foundation of trust, the company has evolved to tackle Indonesia’s broader healthcare challenges through innovation, technology, and a proactive approach.
Also Read: Is blockchain the future of medicine in creating a more secure healthcare?
Bumame now provides modern diagnostic solutions, proactive health screenings, and personalised health guidance.
Indonesia’s healthcare market was valued at approximately US$50 billion in 2024, with an annual growth rate of 11 per cent.
Chandra Tjan, co-founder and General Partner at Alpha JWC Ventures, noted that the funding demonstrates trust in Bumame’s vision. By prioritising technology, proactive care, and high-quality products sourced from top principals with global standards, Bumame ensures that healthcare is both accessible and affordable for all Indonesians.
Alpha JWC Ventures is an early to growth-stage Southeast Asian VC firm with approximately US$650 million assets under management (AUM), while 500 Global is a multi-stage investment firm with US$2.2B in AUM, investing in globally ambitious founders. Kopital Ventures is an early-stage, sector-agnostic VC firm primarily focused on Indonesia, founded in September 2023.
The post Alpha JWC leads pre-Series A round for Indonesian healthtech startup Bumame appeared first on e27.